b2-microglobulin

Prognostic Significance of Thymidine Kinase-1 versus β2-Microglobulin and Lactate Dehydrogenase in Lymphoproliferative Diseases

LYMPHOID TUMORS , , , ,

N.K. Parilova1, N.S. Sergeeva1,2, N.V. Marshutina1, N.G. Tyurina1, I.S. Meisner2

1 P.A. Hertzen Moscow Cancer Research Institute, a branch of the National Medical Research Radiological Center under the Ministry of Health of the Russian Federation, 3 Botkinskii pr-d, Moscow, Russia 125284

2 N.I. Pirogov Russian National Research Medical University under the Ministry of Health of the Russian Federation, 1 Ostrovityanova str., Moscow, Russian Federation, 117997

For correspondence: Natal’ya Konstantinovna Parilova, junior researcher, 3 2nd Botkinskii pr-d, Moscow, Russia, 125284; Tel.: + 7(495)945-74-15; e-mail: parilochka@mail.ru.

For citation: Parilova NK, Sergeeva NS, Marshutina NV, et al. Prognostic Significance of Thymidine Kinase-1 versus b2-Microglobulin and Lactate Dehydrogenase in Lymphoproliferative Diseases. Clinical oncohematology. 2016;9(1):6–12 (In Russ).

DOI: 10.21320/2500-2139-2016-9-1-6-12

ABSTRACT

Background & Aims. Lactate dehydrogenase (LDH) and b2-microglobulin (b2-MG) are usually detected as serological tumor markers (TM) in malignant lymphoproliferative diseases (LPD); however, their use in monitoring of chemotherapy (CT) is limited due to their low sensitivity and specificity. The aim of this paper is to evaluate the prognostic value of baseline levels of thymidine kinase-1 (TK-1) versus b2-MG and LDH in patients with non-Hodgkin’s lymphomas (NHL) and Hodgkin’s lymphoma (HL) and to assess their clinical significance of changes in these parameters during CT as criteria of its effectiveness.

Methods. TK-1, b2-MG and LDH levels were evaluated in 61 NHL patients and 34 HL patients at baseline and after each subsequent CT cycle. The average age of patients enrolled in the study was 42.5 years (range 18–77 years). Of them 45 were men and 50 were women. Marker levels were determined in serum using the following tests: enzyme-linked immunosorbent assay (ELISA) for TK-1, immunoturbidimetry for b2-MG, and biochemical method for LDH. Discriminatory levels specified by test-system manufacturers were used in calculations: 50 DU/l for TK-1, 800–2400 mg/l for b2-MG, and 225–450 U/l for LDH.

Results. The study demonstrated that lower baseline levels of all three TM were associated with higher probability of complete or partial remission, and the statistical difference was higher. Baseline levels of TK-1 < 150 DU/l and b2-MG < 2200 mg/l may serve as prognostic factors of higher probability of achievement of complete or partial remission.

Conclusion. 4-fold increase in TK-1 serum activity from baseline after the 1st course of CT can predict the effectiveness of antitumor therapy. At the same time, no significant associations between b2-MG and LDH serum levels changes during the treatment and efficacy of the treatment were found.

Keywords: thymidine kinase-1, b2-microglobulin, lactate dehydrogenase, Hodgkin’s lymphoma, non-Hodgkin’s lymphomas.

Received: June 17, 2015

Accepted: November 3, 2015

Read in PDF (RUS)pdficon

REFERENCES

  1. Павлова О.А., Тюрина Н.Г. Лимфома Ходжкина. Лимфопролиферативные опухоли. В кн.: Онкология. Клинические рекомендации. Под ред. В.И. Чиссова, С.Л. Дарьяловой. 2-е изд., испр. и доп. М.: ГЭОТАР-Медиа, 2009. С. 829–88.
    [Pavlova OA, Tyurina NG. Hodgkin’s lymphoma. Lymphoproliferative diseases. In Chissov VI, Dar’yalova SL, eds. Onkologiya. Klinicheskie rekomendatsii. (Oncology. Clinical recommendations.) 2nd revised edition. Moscow: GEOTAR-Media Publ.; 2009. p. 829–88. (In Russ)]
  2. Долгов В.В., Козлов А.В., Раков С.С. Лабораторная энзимология. М.: Витал Диагностикс, 2002. С. 104–18.
    [Dolgov VV, Kozlov AV, Rakov SS. Laboratornaya enzimologiya. (Laboratory methods in enzymology.) Moscow: Vital Diagnostiks Publ.; 2002. p. 104–18. (In Russ)]
  3. Bien E, Balcerska A. Serum soluble interleukin-2 receptor, beta2-microglobulin, lactate dehydrogenase and erythrocyte sedimentation rate in children with Hodgkin’s lymphoma. Scand J Immunol. 2009;70(5):490–500. doi: 10.1111/j.1365-3083.2009.02313.x.
  4. Shipp MA, Harrington DP, Andersen JR, et al. A predictive model for aggressive non-Hodgkin’s lymphoms. N Engl J Med. 1993;329(14):987–94. doi: 10.1056/nejm199309303291402.
  5. Дати Ф., Метцманн Э. Белки. Лабораторные тесты и их клиническое применение: Пер. с англ. М.: Лабора, 2007. 560 с.
    [Dati F, Metzman E. Proteins. Laboratory testing and clinical use. Holzheim; 2005. (Russ. ed.: Dati F, Metzman E. Belki. Laboratornye testy i ikh klinicheskoe primenenie. Moscow: Labora Publ.; 2007. 560 p.)]
  6. Votava T, Topolcan O, Holubec L Jr, et al. Changes of serum thymidine kinase in children with acute leukemia. Anticancer Res. 2007;27(4A):1925–8.
  7. Chen F, Tang L, Xia T, et al. Serum thymidine kinase 1 levels predict cancer-free survival following neoadjuvant, surgical and adjuvant treatment of patients with locally advanced breast cancer. Mol Clin Oncol. 2013;1(5):894–902. doi: 10.3892/mco.2013.149.
  8. Chen Y, Ying M, Chen YS, et al. Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1,247 cancer patients in routine clinical settings. Int J Clin Oncol. 2010;15(4):359–68. doi: 10.1007/s10147-010-0067-4.
  9. Pan ZL, Ji XY, Shi YM, et al. Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin’s lymphoma patients. J Cancer Res Clin Oncol. 2010;136(8):1193–9. doi: 10.1007/s00432-010-0769-z.
  10. Парилова Н.К., Сергеева Н.С., Тюрина Н.Г. и др. Сывороточные уровни тимидинкиназы-1 (ТК-1) у больных с лимфопролиферативными заболеваниями. Онкология. Журнал им. П.А. Герцена. 2012;1:33–8.
    [Parilova NK, Sergeeva NS, Tyurina NG, et al. Serum thymidine kinase 1 (TK-1) levels in patients with lymphoproliferative disorders. Onkologiya. Zhurnal im PA Gertsena. 2012;1:33–8. (In Russ)]
  11. Bogni A, Cortinois A, Grasseli G, et al. Thymidine kinase (TK) activity as a prognostic parameter of survival in lymphoma patients. J Biol Regul Homeost Agents. 1994;8(4):10.
  12. Nisman B, Nechushtan H, Biran H, et al. Serum thymidine kinase 1 activity in the prognosis and monitoring of chemotherapy in lung cancer patients: a brief report. J Thorac Oncol. 2014;9(10):1568–72. doi: 10.1097/jto.0000000000000276.
  13. Nisman B, Nchushtan H, Biran H, et al. Serum thymidine kinase 1 activity in prognosis and monitoring chemotherapy in lung cancer patients. Tumor Biol. 2014;35(1):22–3. doi: 10.1097/jto.0000000000000276.